MMP-11 Levels and Outcomes in Advanced Gastric Cancer
Author Information
Author(s): Yan Dong, Dai Hong, Liu Jin-Wei
Primary Institution: Beijing Chao-Yang Hospital affiliated with Capital Medical University
Hypothesis
Does the serum level of MMP-11 predict responses to chemotherapy and prognosis in advanced gastric adenocarcinoma?
Conclusion
Serum levels of MMP-11 are not associated with chemotherapy response but are linked to lymph node metastasis and prognosis.
Supporting Evidence
- MMP-11 levels were significantly higher in patients with advanced gastric adenocarcinoma compared to healthy controls.
- Patients with low MMP-11 levels had a higher median survival time than those with high levels.
- MMP-11 levels correlated with lymph node metastasis.
Takeaway
This study looked at a protein called MMP-11 in patients with stomach cancer. It found that while MMP-11 levels don't help predict how well chemotherapy will work, they can give clues about how serious the cancer is.
Methodology
The study reviewed clinical data from 86 patients with advanced gastric adenocarcinoma, analyzing serum MMP-11 levels before and after chemotherapy.
Potential Biases
Potential biases due to the retrospective nature of the study and selection of patients.
Limitations
The study is retrospective and may not account for all variables affecting survival.
Participant Demographics
60 males and 26 females, median age 51 years.
Statistical Information
P-Value
0.017
Confidence Interval
95%CI: 1.288-5.320
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website